Study of QL706 plus chemo for resistant cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new treatment (QL706) combined with chemotherapy, with or without bevacizumab, for cervical cancer that has stopped responding to previous immunotherapy. It aims to find a better option for patients whose disease has progressed after anti-PD-1/PD-L1 therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your cervical cancer has come back or spread to other parts of the body.
- You have at least one tumor that can be measured on a scan.
- You are in fairly good health, able to do daily activities with little or no help.
- You have tried at least one prior immunotherapy drug (like pembrolizumab or nivolumab) and your cancer got worse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called QL1706 for people with cervical cancer that has come back or spread and has not responded to platinum-based chemotherapy. It aims to see if QL1706 can help shrink tumors and improve outcomes.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a new drug called QL1706 for people with cervical cancer that has spread and no longer responds to PD-1/PD-L1 therapy. It may offer a new treatment option if you have tried this type of immunotherapy before.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a combination of an immunotherapy drug (QL1706) and a nine-strain HPV vaccine as a first treatment for cervical cancer that has come back, spread, or persists. It aims to see if this approach can help people with persistent, recurrent, or metastatic cervical cancer who have not had prior systemic therapy.
Hear when a new Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.